老虎证券

BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial

Reuters
2025/12/08
BUZZ-<a href="https://laohu8.com/S/RXRX">Recursion</a> climbs as experimental drug reduces polyp growth in rare disease trial

** Shares of drug developer Recursion Pharma RXRX.O rise 6.2% to $5.05 premarket

** Co says its experimental oral drug, REC-4881, helped reduce abnormal growths, called polyps, in the colon of patients with a rare genetic condition called familial adenomatous polyposis

** In an early to mid-stage trial, 9 out of 11 patients maintained a durable reduction in total polyp burden, 12 weeks after discontinuing therapy

** Co is looking to expand the study to a broader population of patients aged 18 years and above

** Up to last close, stock down 30.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10